Gylden Pharma raises £210.7k for synthetic vaccine development

Synthetic T cell-priming vaccines and immunotherapies are being developed by Gylden Pharma Limited to combat viral and bacterial infectious diseases. The Abingdon-based biotechnology company recently secured £210.7k in a new funding round. This capital injection follows a £3.8m Series A round in October 2025 and several smaller allotments including £836.2k in December 2024 and £176.8k in March 2024.

Founded in 2016, Gylden Pharma focuses on providing broad immunity against global health threats such as betacoronaviruses, dengue, and influenza. The company utilizes a proprietary MHC Class I Ligandome Library and a nanocluster carrier system to deliver synthetic peptides to the skin-resident immune system. This approach triggers a cellular immune response to destroy pathogen-infected cells.

The delivery method relies on Microneedle Array Patch (MAP) transdermal technology, which Gylden Pharma acquired from Zosano Pharma in 2022. This skin-based immunisation aims to reduce the logistical burdens associated with traditional vaccination methods. Beyond its core infectious disease pipeline, the firm is developing a patch-based therapeutic for migraines and candidates for cardiometabolic disorders and cancer immunotherapy.

Gylden Pharma maintains its headquarters in Oxfordshire, with R&D and GMP manufacturing facilities located in Milton Park. Its international operations include a subsidiary in Doylestown, Pennsylvania, and a manufacturing facility in Fremont, California. Financial records for the year ended 31 March 2025 show the company employs 36 people.

The company has a history of capital raises, including a £10.1m Series A round in January 2022 and a £8.2m round in August 2023. Other previous funding includes £3.7m in November 2021 and £6.5m in September 2020. (The latest allotment and filing documentation were processed in May 2026).